KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -14.38%.

  • Neogenomics' EBITDA Margin fell 175.00% to -14.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.04%, marking a year-over-year decrease of 272.00%. This contributed to the annual value of -13.94% for FY2024, which is 427.00% up from last year.
  • Neogenomics' EBITDA Margin amounted to -14.38% in Q3 2025, which was up 45.23% from -26.27% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' EBITDA Margin registered a high of -10.70% during Q4 2024, and its lowest value of -44.40% during Q1 2022.
  • In the last 3 years, Neogenomics' EBITDA Margin had a median value of -15.92% in 2023 and averaged -17.02%.
  • In the last 5 years, Neogenomics' EBITDA Margin slumped by 3,746bps in 2021 and then spiked by 1,884bps in 2023.
  • Neogenomics' EBITDA Margin (Quarterly) stood at -33.06% in 2021, then skyrocketed by 1,404bps to -19.02% in 2022, then skyrocketed by 708bps to -11.94% in 2023, then skyrocketed by 124bps to -10.70% in 2024, then slumped by 175bps to -14.38% in 2025.
  • Its EBITDA Margin stands at -14.38% for Q3 2025, versus -26.27% for Q2 2025 and -16.56% for Q1 2025.